Associations of fibroblast growth factor 21 with cardiovascular risk and beta-cell function in patients who had no history of diabetes

作者：Wang Jun Sing; Sheu Wayne Huey Herng; Lee Wen Jane; Lee I Te; Lin Shih Yi; Lee Wen Lieng; Liang Kae Woei; Lin Shing Jong^*

来源：Clinica Chimica Acta, 2017, 472: 80-85.

DOI：10.1016/j.cca.2017.07.017

• Cardiovascular
• Coronary artery disease
• Fibroblast growth factor 21
• Oral glucose tolerance test
• beta-cell function

Background: We investigated the associations of fibroblast growth factor 21 (FGF-21) with cardiovascular risk and beta-cell function in patients who had no history of diabetes.
Methods: We enrolled 269 outpatients who had been referred for an oral glucose tolerance test (OGTT). Plasma glucose, insulin, and FGF-21 were measured before and at 2 h after the OGTT. beta-cell function was assessed using the insulinogenic index, corrected for insulin resistance. Patients' 10-year coronary heart disease (CHD) risk was assessed using the Chinese Multi-provincial Cohort Study functions.
Results: Overall, there was a 10% decrease in FGF-21 after OGTT (p < 0.001). The decrease of FGF-21 after OGTT in patients with normal glucose tolerance, prediabetes, and diabetes was 8%, 10%, and 21%, respectively (all p < 0.05). Patients with a history of admission for coronary angiography had a higher 10-year CHD risk and fasting FGF-21 (both p < 0.001). In multivariate regression analysis, fasting FGF-21 was positively associated with 10-year CHD risk, while FGF-21 relative change 2 h after OGTT was positively associated with beta-cell function.
Conclusions: In patients who had no history of diabetes, fasting FGF-21 was positively associated with 10-year CHD risk, while FGF-21 relative change 2 h after OGTT was positively associated with beta-cell function.

• 出版日期2017-9
• 单位河北医科大学